81 related articles for article (PubMed ID: 37140194)
1. Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients.
Liu F; Wang F; He J; Zhou S; Luo M
Cancer Med; 2023 Jun; 12(12):13123-13134. PubMed ID: 37140194
[TBL] [Abstract][Full Text] [Related]
2. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Iams WT; Yu H; Shyr Y; Patil T; Horn L; McCoach C; Kelly K; Doebele RC; Camidge DR
Clin Lung Cancer; 2018 Nov; 19(6):531-543. PubMed ID: 30197261
[TBL] [Abstract][Full Text] [Related]
3. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
Barsouk A; Friedes C; Iocolano M; Doucette A; Cohen RB; Robinson KW; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Levin WP; Cengel KA; Bradley JD; Feigenberg SJ; Sun L; Aggarwal C; Langer CJ; Yegya-Raman N
Clin Lung Cancer; 2024 May; 25(3):e161-e171. PubMed ID: 38195320
[TBL] [Abstract][Full Text] [Related]
4. Impact of KRAS
Caballé-Perez E; Hernández-Pedro N; Ramos-Ramírez M; Barrios-Bernal P; Romero-Núñez E; Lucio-Lozada J; Ávila-Ríos S; Reyes-Terán G; Cardona AF; Arrieta O
Clin Transl Oncol; 2024 Apr; 26(4):836-850. PubMed ID: 37490263
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
[TBL] [Abstract][Full Text] [Related]
6. Single agent VS-6766 or VS-6766 plus defactinib in
Capelletto E; Bironzo P; Denis L; Koustenis A; Bungaro M; Novello S
Future Oncol; 2022 May; 18(16):1907-1915. PubMed ID: 35285277
[TBL] [Abstract][Full Text] [Related]
7. Response to first-line pembrolizumab in metastatic
Rossi S; Pagliaro A; Finocchiaro G; Marinello A; Giordano L; Bria E; Stefani A; Vitale A; Toschi L; D'Argento E; Santoro A
Future Oncol; 2024 Mar; 20(7):373-380. PubMed ID: 38445372
[No Abstract] [Full Text] [Related]
8. The Prognostic Effect of
Wahl SGF; Dai HY; Emdal EF; Berg T; Halvorsen TO; Ottestad AL; Lund-Iversen M; Brustugun OT; Førde D; Paulsen EE; Donnem T; Andersen S; Grønberg BH; Richardsen E
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503114
[TBL] [Abstract][Full Text] [Related]
9. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38625494
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
Thomas QD; Quantin X; Lemercier P; Chouaid C; Schneider S; Filleron T; Remon-Masip J; Perol M; Debieuvre D; Audigier-Valette C; Justeau G; Loeb A; Hiret S; Clement-Duchene C; Dansin E; Stancu A; Pichon E; Bosquet L; Girard N; Du Rusquec P
ESMO Open; 2024 Jun; 9(6):103473. PubMed ID: 38833966
[TBL] [Abstract][Full Text] [Related]
11. Presentation and outcomes of KRAS
Esfahanian N; Chan SWS; Zhan LJ; Brown MC; Khan K; Lee J; Balaratnam K; Yan E; Parker J; Garcia-Pardo M; Barghout SH; Eng L; Bradbury PA; Shepherd FA; Leighl NB; Sacher AG; Snow S; Juergens R; Liu G
Cancer Treat Res Commun; 2023; 37():100774. PubMed ID: 37979334
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study.
Tsiouda T; Domvri K; Boutsikou E; Bikos V; Kyrka K; Papadaki K; Pezirkianidou P; Porpodis K; Cheva A
J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793038
[TBL] [Abstract][Full Text] [Related]
13. Chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations (2023 edition).
Society of Cancer Precision Medicine of Chinese Anti-Cancer Association; The Lung Cancer Expert Group of Chinese Medical Association Publishing House
Chin Med J (Engl); 2024 May; 137(9):1016-1018. PubMed ID: 38454303
[No Abstract] [Full Text] [Related]
14. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
15. Reduced dynamic complexity allows structure elucidation of an excited state of KRAS
Chao FA; Chan AH; Dharmaiah S; Schwieters CD; Tran TH; Taylor T; Ramakrishnan N; Esposito D; Nissley DV; McCormick F; Simanshu DK; Cornilescu G
Commun Biol; 2023 Jun; 6(1):594. PubMed ID: 37268708
[TBL] [Abstract][Full Text] [Related]
16. KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.
Gallina FT; Marinelli D; Melis E; Forcella D; Taje R; Buglioni S; Visca P; Torchia A; Cecere FL; Botticelli A; Santini D; Ciliberto G; Cappuzzo F; Facciolo F
Lung Cancer; 2023 Jul; 181():107254. PubMed ID: 37253296
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract][Full Text] [Related]
18. RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.
Miller-Phillips L; Collisson EA
Curr Treat Options Oncol; 2023 Aug; 24(8):1088-1101. PubMed ID: 37296367
[TBL] [Abstract][Full Text] [Related]
19. A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics.
SantaLucia J
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1460-5. PubMed ID: 9465037
[TBL] [Abstract][Full Text] [Related]
20. Dependence of the melting temperature of DNA on salt concentration.
Schildkraut C
Biopolymers; 1965; 3(2):195-208. PubMed ID: 5889540
[No Abstract] [Full Text] [Related]
[Next] [New Search]
